Aquatic Capital Management LLC Buys New Shares in Boston Scientific Corporation $BSX

Key Points

• Aquatic Capital Management opened a new position in Boston Scientific (NYSE:BSX) in Q3, buying 331,100 shares valued at about $32.3 million.
• CEO Michael F. Mahoney sold 160,901 shares on Feb. 2 for roughly $15.0 million, reducing his ownership by about 10.23%.
• Boston Scientific is facing coordinated class‑action litigation alleging misrepresentation of U.S. electrophysiology volumes and recent analyst price‑target cuts, while institutional investors own about 89.07% of the stock.

Aquatic Capital Management LLC bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 331,100 shares of the medical equipment provider's stock, valued at approximately $32,325,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares during the period. State Street Corp lifted its holdings in shares of Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider's stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the period. Norges Bank acquired a new stake in shares of Boston Scientific during the second quarter worth about $2,089,937,000. Invesco Ltd. boosted its position in Boston Scientific by 0.7% in the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider's stock valued at $1,656,131,000 after buying an additional 111,826 shares during the last quarter. Finally, Amundi increased its holdings in Boston Scientific by 17.5% in the 3rd quarter. Amundi now owns 11,981,584 shares of the medical equipment provider's stock worth $1,158,619,000 after buying an additional 1,781,830 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the company's stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.50% of the company's stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $69.15 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The stock has a market capitalization of $102.61 billion, a price-to-earnings ratio of 35.64, a PEG ratio of 0.97 and a beta of 0.69. The firm's 50 day simple moving average is $82.47 and its 200-day simple moving average is $93.29. Boston Scientific Corporation has a 12 month low of $67.56 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion during the quarter, compared to analysts' expectations of $5.29 billion. During the same period in the previous year, the business posted $0.70 EPS. The business's revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. UBS Group reduced their price target on shares of Boston Scientific from $140.00 to $120.00 and set a "buy" rating for the company in a research report on Thursday, February 5th. Evercore cut their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an "outperform" rating on the stock in a research note on Thursday, February 5th. Needham & Company LLC reduced their target price on shares of Boston Scientific from $121.00 to $97.00 and set a "buy" rating for the company in a report on Thursday, February 5th. The Goldman Sachs Group set a $99.00 target price on shares of Boston Scientific in a research report on Thursday, February 5th. Finally, Barclays lowered their price target on shares of Boston Scientific from $136.00 to $124.00 and set an "overweight" rating on the stock in a report on Tuesday, February 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $108.00.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.